
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen is a company with a strong cash position and a positive outlook for growth, evidenced by their record-breaking 1Q26 financial results and 27% YoY revenue growth. With the recent FDA approval of their avance nerve allograft as a biologic, Axogen's market positioning has been further strengthened, and their products are now available in the majority of the country. Based on their projected sales and revenue growth, we believe that the current stock price does not accurately reflect the company's potential for continued expansion and success in the peripheral nerve repair market.
Bears say
Axogen is currently reporting a net loss for the year, despite a significant increase in revenue. This trend indicates that the company has not been able to effectively manage its expenses and achieve profitability, which could negatively affect its long-term financial stability. Additionally, the company's high reliance on investments in commercial infrastructure raises concerns about its future profitability and potential cash flow issues.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares